NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, NRX Pharmaceuticals, Inc. has 43.16M shares outstanding.

As of June 30, 2026, NRX Pharmaceuticals, Inc. maintains a current ratio of 0.86, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -732.94, indicating conservative leverage, while an interest coverage ratio of -16.97 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -120.42, reflecting losses generated across the asset base. The company generates approximately 133,517.67 in revenue per employee across its workforce of 22.25, a quick read on workforce productivity versus industry peers.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, NRX Pharmaceuticals, Inc. generated 2.97M in revenue and converted that into -20.55M in net income, yielding earnings per share of -0.66. EBITDA reached -16.99M, while operating income came in at -17.42M.

As of June 30, 2026, NRX Pharmaceuticals, Inc. holds 23.36M in cash and equivalents against 1.09M in total debt, resulting in a net debt position of -23.00M. Total book value stands at -148,801.00, with working capital of -4.13M providing operational flexibility.

NRX Pharmaceuticals, Inc. produced -17.31M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, NRX Pharmaceuticals, Inc. posted a gross margin of 46.64, reflecting its pricing power and cost economics. The operating margin of -586.24 and net profit margin of -691.81 provide insight into operational efficiency.

NRX Pharmaceuticals, Inc.'s most recent stock split took place on April 2, 2024 with a 10:1 split ratio.